VivoSeq
Other

Keratosis, Actinic

1

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Keratosis, Actinic is an early-stage landscape with 1 program across 0 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Tirbanibulin

Almirall, S.A.

Approved
No programs

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis
Completed·—·Phase 3·NCT06135415·280 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)